AGILeBiotics is a pharmaceutical company focusing on the development of novel antibiotics for the treatment of life-threatening infections by multidrug-resistant bacteria.
AGILeBiotics received a pre-seed investment from three regional investors, i.e. RUG Houdstermaatschappij B.V., Hanzepoort B.V., Stichting Ir. G.J. Smid Fonds. With this financial support, AGILeBiotics has started its drug discovery and development program, and envisions to advance first antibiotic candidates into late pre-clinical development in 2018.